Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
Robert Bradway, chief executive of Thousand Oaks pharma giant Amgen Inc., has grown increasingly frustrated at the government’s unwillingness to come to terms with Amgen over its $27.8 billion acquisition deal of Irish pharma company Horizon Therapeutics.
Shares of Horizon Therapeutics tumbled on Tuesday following a report that the Federal Trade Commission (FTC) is preparing to block its $27.8 billion sale to.
Global Roundup: Singapore Researchers Create Atlas of Gastric Cancer - read this article along with other careers information, tips and advice on BioSpace